LifeWatch AG: Acquisition of FlexLife Health Inc., an INR monitoring company co-founded by the Cleveland Clinic Dienstag, 10. November 2015 - 07:01

LifeWatch AG / Key word(s): Acquisition
LifeWatch AG: Acquisition of FlexLife Health Inc., an INR monitoring
company co-founded by the Cleveland Clinic

10.11.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------

LifeWatch(R) acquires FlexLife Health Inc., an INR monitoring company
co-founded by the Cleveland Clinic

Zug/Switzerland, November 10, 2015 - LifeWatch(R) AG (SIX Swiss Exchange:
LIFE), a leading developer and provider of medical solutions and remote
diagnostic monitoring services in the digital health market, is pleased to
announce the acquisition of FlexLife Health Inc., a company offering remote
patient monitoring services in the area of coagulation measurement, by its
subsidiary, LifeWatch Services Inc.

FlexLife was founded in 2012 by the Cleveland Clinic Foundation and ZIN
Technologies, Inc. (a NASA partner for health in space) to offer home
monitoring solutions for INR (blood clotting) measurement. FlexLife offers
INR monitoring services via a proprietary web-based digital health platform
that is superior to all other current service offerings in the market.
Monitoring of the INR is essential for patients taking drugs like Warfarin
(an oral anticoagulant), which pose a risk of bleeding or clotting if
dosing is not properly monitored.

LifeWatch's electrophysiologist and cardiologist relationship base have
already expressed a deep interest in remote monitoring of INR for their
patients, since the main cause of a clinical arrhythmia, detected by
LifeWatch's existing cardiac devices, is atrial fibrillation for which
Warfarin is a common treatment option. Dr. Stephan Rietiker, CEO of
LifeWatch, stated: "I am excited about this acquisition, particularly since
Warfarin and similar generic anti-coagulants are the most commonly
prescribed ant-coagulant medications in the U.S. The FlexLife product
complements well our existing cardiac monitoring business and will allow us
to provide doctors and their patients needing INR therapy due to atrial
arrhythmias with a unique and easy-to-use product that will improve patient
quality of life."

LifeWatch will integrate this business into its existing operations to
benefit from synergy effects (reimbursement, distribution, etc.) and
profitably grow the business over the next few years. LifeWatch expects to
commence activities already in December this year with a full launch in the
U.S. at the beginning of 2016. The parties have agreed to keep the terms of
the transaction confidential.

 

For further questions:

LifeWatch AG
c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser
Phone: +41 43 268 32 35 / +41 79 410 81 88
E-mail: investor-relations@lifewatch.com 

About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),

Switzerland, is a leading healthcare technology and solution company,
specializing in advanced digital health systems and wireless remote
diagnostic patient monitoring services. LifeWatch's services provide
physicians with critical information to determine appropriate treatment and
thereby improve patient outcomes. LifeWatch AG has operative subsidiaries
in the United States, in Switzerland and in Israel, and is the parent
company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd.
LifeWatch Services, Inc. is a leading U.S.-based provider of cardiac
monitoring services and home sleep testing of Obstructive Sleep Apnea
(OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer
and manufacturer of telemedicine products. For additional information,
please visit www.lifewatch.com.

Sign up for customized e-mail alerts and documentation requests at 
http://www.irlifewatch.com/alert-service.aspx 

This press release includes forward-looking statements. All statements
other than statements of historical facts contained in this press release,
including statements regarding future results of operations and financial
position, the business strategy, and plans and objectives for future
operations, are forward-looking statements. The words "believe," "may,"
"will," "estimate," "continue," "anticipate," "intend," "expect" and
similar expressions are intended to identify forward-looking statements.
LifeWatch AG has based these forward-looking statements largely on current
expectations and projections about future events and financial trends that
it believes may affect the financial condition, results of operations,
business strategy, short-term and long-term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light of
these risks, uncertainties and assumptions, the forward-looking events and
circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only
on data available to LifeWatch AG at the time of the issue of this press
release. LifeWatch AG does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of
new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL
CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN
OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN
THE UNITED STATES, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN
ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED
STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES
SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED
STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM
LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.